Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41581-020-00352-9 http://scihub22266oqcxt.onion/10.1038/s41581-020-00352-9 32901129!7478103!32901129     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32901129&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Nat+Rev+Nephrol 2020 ; 16 (12): 697-699 Nephropedia Template TP {{tp|p=32901129|t=2020. Haemoperfusion should only be used for COVID-19 in the context of randomized trials |pdf=|usr=}}{{32901129}} gab.com Text Haemoperfusion should only be used for COVID-19 in the context of randomized trials JO: Nat Rev Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=32901129 #FOAvip Interest in the use of haemoperfusion for severe COVID-19 has been spurred by anecdotal reports of its efficacy and expert reviews suggesting theoretical benefits. However, on the basis of the limited current evidence, haemoperfusion remains an experimental therapy that should only be applied within the context of well-designed randomized trials. Twit Text FOAVip Haemoperfusion should only be used for COVID-19 in the context of randomized trials ????Nat Rev Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=32901129 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32901129 #FOAvip English Wikipedia <ref>{{Cite pmid|32901129}}</ref> Haemoperfusion should only be used for COVID-19 in the context of randomized trials #MMPMID32901129 Clark EG; Hiremath S; McIntyre L; Wald R; Hundemer GL; Joannidis M Nat Rev Nephrol 2020[Dec]; 16 (12): 697-699 PMID32901129show ga Interest in the use of haemoperfusion for severe COVID-19 has been spurred by anecdotal reports of its efficacy and expert reviews suggesting theoretical benefits. However, on the basis of the limited current evidence, haemoperfusion remains an experimental therapy that should only be applied within the context of well-designed randomized trials. |*Betacoronavirus[MESH] |*Hemoperfusion[MESH] |COVID-19[MESH] |Coronavirus Infections/*complications/*therapy[MESH] |Humans[MESH] |Pandemics[MESH] |Patient Selection[MESH] |Pneumonia, Viral/*complications/*therapy[MESH] |Randomized Controlled Trials as Topic[MESH]Haemoperfusion should only be used for COVID-19 in the context of rand(epmc).pdf DeepDyve Pubget Overpricing